MedKoo Cat#: 522438 | Name: P7C3A20-analog
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

P7C3A20-analog, as known as defluoro-P7C3-A20, is a structural analogue of P7C3-A20. Compared to P7C3-A20 structure, P7C3-A20 analog has no fluorine atom in the 1,3-diaminopropane-bridge. P7C3-A20 analog was synthesized by mistake during a process to make P7C3-A20. The bioactivity of P7C3-A20 analog is unknown. P7C3-A20 analog may be used for research to compare with P7C3-A20. P7C3-A20 is a proneurogenic, neuroprotective agent. P7C3-A20 displayed increased activity and an improved toxicity profile compared to P7C3. P7C3-A20 demonstrated greater proneurogenic efficacy than a wide spectrum of currently marketed antidepressant drugs. P7C3-A20 showed neuroprotective properties in rodent models of Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury and age-related cognitive decline.

Chemical Structure

P7C3A20-analog
P7C3A20-analog
CAS#unknown as of 10/13/2015

Theoretical Analysis

MedKoo Cat#: 522438

Name: P7C3A20-analog

CAS#: unknown as of 10/13/2015

Chemical Formula: C22H20Br2N2O

Exact Mass: 485.9942

Molecular Weight: 488.22

Elemental Analysis: C, 54.12; H, 4.13; Br, 32.73; N, 5.74; O, 3.28

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
P7C3-A20 analog; P7C3A20 analog; P7C3-A20-analog; defluoro-P7C3-A20. P7C3A20-analog
IUPAC/Chemical Name
N-(3-(3,6-dibromo-9H-carbazol-9-yl)propyl)-3-methoxyaniline
InChi Key
KQQDARPZXLJWEC-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H20Br2N2O/c1-27-18-5-2-4-17(14-18)25-10-3-11-26-21-8-6-15(23)12-19(21)20-13-16(24)7-9-22(20)26/h2,4-9,12-14,25H,3,10-11H2,1H3
SMILES Code
COC1=CC(NCCCN2C3=C(C4=C2C=CC(Br)=C4)C=C(Br)C=C3)=CC=C1
Appearance
White solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
P7C3A20-analog, as known as defluoro-P7C3-A20, is a structural analogue of P7C3-A20.
In vitro activity:
The aim of this study was to investigate the effect of a potential NAMPT activator, P7C3-A20, an aminopropyl carbazole derivative, on ischemic stroke. In vitro study, neuron protection effect of P7C3-A20 was investigated by co-incubation with primary neurons subjected to oxygen-glucose deprivation (OGD) or oxygen-glucose deprivation/reperfusion (OGD/R) injury. In order to explore the role of P7C3‐A20 in cerebral ischemia, this study cultured primary cortical neurons and established neuronal OGD model to mimic in vitro ischemic stress. Primary cortical neurons were exposed to OGD condition for 1.5 and 12 h, respectively. This study found that neuronal injuries were growing worse following prolonged duration of OGD. Prolonged administration of P7C3‐A20 may have positive effects for the recovery of chronic stroke. Furthermore, P7C3‐A20 may benefit poststroke recovery because of its role in neurogenesis, given evidence that P7C3‐A20 could rescue NPAS3−/−‐induced loss of hippocampal neurogenesis, and augment hippocampal neurogenesis. CNS Neurosci Ther. 2016 Sep; 22(9): 782–788. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492790/
In vivo activity:
This laboratory model produces neurodegeneration and neurobehavioral deficits reminiscent of TBI in people. Mice were treated and analyzed beginning 1 y after a single injury, as outlined in Fig. 1A. Two-month-old mice were subjected to TBI or sham-TBI and housed under standard conditions for 1 y. Mice were then administered either vehicle (TBI-Veh, Sham-Veh) or P7C3-A20 (10 mg⋅kg−1⋅day−1 intraperitoneally [IP]; TBI-P7C3-A20) for 4 wk. Animals were then housed under standard conditions with no treatment for four additional months (Fig. 1A). At 19 mo of age (17 mo postinjury), TBI-Veh mice exhibited impaired learning (Fig. 1B) and memory (Fig. 1C) whereas TBI-P7C3-A20 mice again performed as well as Sham-Veh animals. P7C3-A20 directly protects brain microvascular endothelial cells in vivo in mice and in cultured human cells. Taken together, the results suggest that BBB deterioration may be a major contributor to chronic neurodegeneration after remote TBI and that its repair may halt this pathology. Proc Natl Acad Sci U S A. 2020 Nov 3; 117(44): 27667–27675. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959512/

Preparing Stock Solutions

The following data is based on the product molecular weight 488.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wang SN, Xu TY, Wang X, Guan YF, Zhang SL, Wang P, Miao CY. Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke. CNS Neurosci Ther. 2016 Sep;22(9):782-8. doi: 10.1111/cns.12576. Epub 2016 Jun 23. PMID: 27333812; PMCID: PMC6492790. 2. Vázquez-Rosa E, Shin MK, Dhar M, Chaubey K, Cintrón-Pérez CJ, Tang X, Liao X, Miller E, Koh Y, Barker S, Franke K, Crosby DR, Schroeder R, Emery J, Yin TC, Fujioka H, Reynolds JD, Harper MM, Jain MK, Pieper AA. P7C3-A20 treatment one year after TBI in mice repairs the blood-brain barrier, arrests chronic neurodegeneration, and restores cognition. Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27667-27675. doi: 10.1073/pnas.2010430117. Epub 2020 Oct 21. PMID: 33087571; PMCID: PMC7959512. 3. Hill CS, Menon DK, Coleman MP. P7C3-A20 neuroprotection is independent of Wallerian degeneration in primary neuronal culture. Neuroreport. 2018 Dec 12;29(18):1544-1549. doi: 10.1097/WNR.0000000000001146. PMID: 30334859; PMCID: PMC6250284.
In vitro protocol:
1. Wang SN, Xu TY, Wang X, Guan YF, Zhang SL, Wang P, Miao CY. Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke. CNS Neurosci Ther. 2016 Sep;22(9):782-8. doi: 10.1111/cns.12576. Epub 2016 Jun 23. PMID: 27333812; PMCID: PMC6492790.
In vivo protocol:
1. Vázquez-Rosa E, Shin MK, Dhar M, Chaubey K, Cintrón-Pérez CJ, Tang X, Liao X, Miller E, Koh Y, Barker S, Franke K, Crosby DR, Schroeder R, Emery J, Yin TC, Fujioka H, Reynolds JD, Harper MM, Jain MK, Pieper AA. P7C3-A20 treatment one year after TBI in mice repairs the blood-brain barrier, arrests chronic neurodegeneration, and restores cognition. Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27667-27675. doi: 10.1073/pnas.2010430117. Epub 2020 Oct 21. PMID: 33087571; PMCID: PMC7959512. 2. Hill CS, Menon DK, Coleman MP. P7C3-A20 neuroprotection is independent of Wallerian degeneration in primary neuronal culture. Neuroreport. 2018 Dec 12;29(18):1544-1549. doi: 10.1097/WNR.0000000000001146. PMID: 30334859; PMCID: PMC6250284.